News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Noxopharm.
RELATED STOCKHEAD STORIES
News
Closing Bell: Buyers ambush benchmark setting new benchmark
News
ASX Small Caps Lunch Wrap: Who’s thrown a giant sexy spanner in the works this week?
News
Market Highlights: Microsoft’s new AI chip, why divvy stocks aren’t a sure thing, and 5 small caps to watch
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Even the Aussie dollar appreciates a good lead as dynamic surge makes local IT the it sector for a day
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Biotech October Winners: Dimerix, Noxopharm and Chimeric dominate as investors hunt next big thing in pharma
Health & Biotech
mRNA is the next big thing in medicine. Here’s why Noxopharm could be the ASX front runner in this field
Health & Biotech
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News
ASX Small Caps Lunch Wrap: Which tiny Scottish village has a killer clown problem this week?
Health & Biotech
ASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 study
News
Top 10 at 11: Takeover talks and great drugs have everyone excited, but Credit Corp’s found a $45m hole
News
Market Highlights: Nvidia tumbles on US sanctions, oil jumps higher again, and 5 ASX small caps to watch
News
ASX Small Caps Lunch Wrap: Who’s figured out that getting your cats high is purrfectly fine today?
News
ASX Small Caps and IPO Weekly Wrap: ASX biotechs make hay as bond markets boil
News